JP2023531508A - 出血性ショックを処置するための組成物および方法 - Google Patents

出血性ショックを処置するための組成物および方法 Download PDF

Info

Publication number
JP2023531508A
JP2023531508A JP2022579666A JP2022579666A JP2023531508A JP 2023531508 A JP2023531508 A JP 2023531508A JP 2022579666 A JP2022579666 A JP 2022579666A JP 2022579666 A JP2022579666 A JP 2022579666A JP 2023531508 A JP2023531508 A JP 2023531508A
Authority
JP
Japan
Prior art keywords
hboc
plasma
weight
oxygenated
supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531508A5 (enExample
Inventor
ライト，ウィリアム，リチャード，サード
Original Assignee
ヴィルテック バイオ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィルテック バイオ，インク． filed Critical ヴィルテック バイオ，インク．
Publication of JP2023531508A publication Critical patent/JP2023531508A/ja
Publication of JP2023531508A5 publication Critical patent/JP2023531508A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022579666A 2020-06-23 2021-06-23 出血性ショックを処置するための組成物および方法 Pending JP2023531508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042668P 2020-06-23 2020-06-23
US63/042,668 2020-06-23
PCT/US2021/038606 WO2021262803A1 (en) 2020-06-23 2021-06-23 Compositions and methods for treating hemorrhagic shock

Publications (2)

Publication Number Publication Date
JP2023531508A true JP2023531508A (ja) 2023-07-24
JP2023531508A5 JP2023531508A5 (enExample) 2024-07-01

Family

ID=79281812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579666A Pending JP2023531508A (ja) 2020-06-23 2021-06-23 出血性ショックを処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20230241184A1 (enExample)
EP (2) EP4782058A2 (enExample)
JP (1) JP2023531508A (enExample)
AU (1) AU2021297879A1 (enExample)
CA (1) CA3183555A1 (enExample)
ES (1) ES3073540T3 (enExample)
WO (1) WO2021262803A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025091017A1 (en) * 2023-10-27 2025-05-01 Ohio State Innovation Foundation Synthetic whole blood substitutes
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219335A1 (en) * 2004-01-27 2007-09-20 Page Thomas C Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
JP2012529531A (ja) * 2009-06-09 2012-11-22 プロロング ファーマシューティカルズ，エルエルシー ヘモグロビン組成物
WO2015076285A1 (ja) * 2013-11-21 2015-05-28 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
JP2017526740A (ja) * 2014-08-08 2017-09-14 ヴィンディコ ナノバイオテクノロジー， エルエルシー 腫瘍のナノ粒子媒介微小血管塞栓形成を誘導するための組成物および方法
US20200078407A1 (en) * 2018-09-11 2020-03-12 Cellphire, Inc. Blood plasma-containing compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5407579A (en) 1993-07-02 1995-04-18 National Science Council Hemoglobin purification
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
JP3664328B2 (ja) 1996-01-19 2005-06-22 富士写真フイルム株式会社 血漿または血清試料の調製方法
CA2254223A1 (en) 1998-11-16 2000-05-16 Biophys, Inc. Device and method for analyzing a biologic sample
US6518010B2 (en) * 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
US7144989B2 (en) 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
TWI332813B (en) 2007-05-11 2010-11-01 Unimicron Technology Corp Process of structure with embedded circuit
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
BRPI1006722A2 (pt) 2009-04-09 2017-10-10 Entegrion Inc "método de preparação de hemoderivados desidratado, hemoderivados desidratados, bandagem ou auxílio cirúrgico, método para a preparação de plaquetas sanguíneas fixas desidratadas, plaquetas sanguíneas fixas desidratadas, método para o tratamento de um paciente que sofre de um distúrbio sanguíneo e plaquetas de sangue fixas secas por atomização tendo geometria com cavidades esféricas"
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US20120028899A1 (en) 2010-07-30 2012-02-02 Andre Francis Palmer Composition and process for synthesizing tense and relaxed state polymerized hemoglobin
US8609815B2 (en) 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
US10426820B2 (en) 2011-04-13 2019-10-01 Case Western Reserve University Synthetic platelets
WO2014033208A1 (en) 2012-08-30 2014-03-06 Qiagen Gmbh A method for obtaining blood plasma from a whole blood sample
US9304142B1 (en) 2013-03-12 2016-04-05 A. Steve Gurganian Energy harvesting zero-speed sensor device, method and system
CA3143968A1 (en) * 2019-07-02 2021-02-25 Hbo2 Therapeutics, Llc Hemoglobin substitute mixtures including reconstituted plasma and platelets and their manufacture and use
US20210023140A1 (en) 2019-07-26 2021-01-28 Prp Scientific, Inc. Platelet formulations and medical uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219335A1 (en) * 2004-01-27 2007-09-20 Page Thomas C Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
JP2012529531A (ja) * 2009-06-09 2012-11-22 プロロング ファーマシューティカルズ，エルエルシー ヘモグロビン組成物
WO2015076285A1 (ja) * 2013-11-21 2015-05-28 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
JP2017526740A (ja) * 2014-08-08 2017-09-14 ヴィンディコ ナノバイオテクノロジー， エルエルシー 腫瘍のナノ粒子媒介微小血管塞栓形成を誘導するための組成物および方法
US20200078407A1 (en) * 2018-09-11 2020-03-12 Cellphire, Inc. Blood plasma-containing compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNALS OF EMERGENCY MEDICINE, vol. 68(4s), JPN6025017395, 2016, pages 120 - 310, ISSN: 0005731639 *
J. TRAUMA ACUTE CARE SURG., vol. 87(1), Supplement 1, JPN6025017396, 2019, pages 83 - 90, ISSN: 0005731638 *

Also Published As

Publication number Publication date
ES3073540T3 (en) 2026-07-13
EP4167961B1 (en) 2026-04-29
EP4167961A4 (en) 2024-03-13
EP4167961C0 (en) 2026-04-29
US20230241184A1 (en) 2023-08-03
AU2021297879A1 (en) 2023-02-09
CA3183555A1 (en) 2021-12-30
EP4782058A2 (en) 2026-07-29
WO2021262803A1 (en) 2021-12-30
EP4167961A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
EP0277289B2 (en) Extra pure semi-synthetic blood substitute
US5084558A (en) Extra pure semi-synthetic blood substitute
US6506725B1 (en) Ultra pure hemoglobin solutions and blood-substitutes
US6884573B2 (en) Fixed dried red blood cells and method of use
Brzica et al. Autologous blood transfusion
Elmer et al. Hemoglobin-based oxygen carriers for hemorrhagic shock
CN111406737B (zh) 用于器官持续维持的成分、装置和方法
US20090163418A1 (en) Resuscitation fluid
EP4167961B1 (en) Compositions and methods for treating hemorrhagic shock
CN101489581A (zh) 用交联血红蛋白血液代用品治疗急性失血性贫血的方法
JP4581110B2 (ja) ヘモグロビンの精製方法
CN100534534C (zh) 用储存的红血球改善氧传送的方法
Stollings et al. Oxygen therapeutics: Oxygen delivery without blood
Evarts Low molecular weight dextran
EP1773118A2 (en) Lysine citrate for plasma protein and donor protection
Standl Artificial oxygen carriers as red blood cell substitutes–perfluorocarbons and cell-free hemoglobin
Harmening et al. Red Blood Cell, and Platelet Preservation: Historical Perspective, Review of Metabolism and Current Trends
US20090123907A1 (en) Lysine citrate for plasma protein and donor protection
US20240049700A1 (en) Lipid layer preservation
Anthony et al. Indications for Transfusion
Rodwig Concepts of Replacement Therapy: Blood Components, Blood Derivatives, and Medications
Bull Transfusion fluids
Wong The Development of PolyHb-Fg: a novel blood substitute with the potential to support coagulation
Wegener et al. 42-Day Stored RBCs Diluted with Additive Solution Exhibit Decreased Hemolysis
Schimmel The Present Status of Blood Substitutes: A Review of the Literature

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260518